Search

Your search keyword '"Stauch, Martina"' showing total 184 results
Start Over Author "Stauch, Martina"
184 results on '"Stauch, Martina"'

1. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Author

Fischer, Laura E., Stintzing, Sebastian, von Weikersthal, Ludwig Fischer, Modest, Dominik P., Decker, Thomas, Kiani, Alexander, Kaiser, Florian, Al-Batran, Salah-Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Stauch, Martina, Scheithauer, Werner, Giessen-Jung, Clemens, Uhlig, Jens, Peuser, Bettina, Denzlinger, Claudio, Stahler, Arndt, Weiss, Lena, Heinrich, Kathrin, Held, Swantje, Jung, Andreas, Kirchner, Thomas, and Heinemann, Volker

Published
2022
Full Text
View/download PDF

2. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Author

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fürstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Müller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael

Published
2022
Full Text
View/download PDF

5. S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

Author

Langerbeins, Petra, primary, Robrecht, Sandra, additional, Nieper, Pascal, additional, Cramer, Paula, additional, Fürstenau, Moritz, additional, Al-Sawaf, Othman, additional, Fink, Anna-Maria, additional, Kreuzer, Karl-Anton, additional, Vehling-Kaiser, Ursula, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Müller, Lothar, additional, Eckart, Michael, additional, Schlag, Rudolf, additional, Freier, Werner, additional, Gaska, Tobias, additional, Balser, Christina, additional, Reiser, Marcel, additional, Stauch, Martina, additional, Wendtner, Clemens, additional, Fischer, Kirsten, additional, Stilgenbauer, Stephan, additional, Eichhorst, Barbara, additional, and Hallek, Michael, additional

Published
2023
Full Text
View/download PDF

6. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

7. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Author

Stintzing, Sebastian, Modest, Dominik P, Rossius, Lisa, Lerch, Markus M, von Weikersthal, Ludwig Fischer, Decker, Thomas, Kiani, Alexander, Vehling-Kaiser, Ursula, Al-Batran, Salah-Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Stauch, Martina, Scheithauer, Werner, Held, Swantje, Giessen-Jung, Clemens, Moehler, Markus, Jagenburg, Andreas, Kirchner, Thomas, Jung, Andreas, and Heinemann, Volker

Published
2016
Full Text
View/download PDF

8. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Author

Rummel, Mathias, Kaiser, Ulrich, Balser, Christina, Stauch, Martina, Brugger, Wolfram, Welslau, Manfred, Niederle, Norbert, Losem, Christoph, Boeck, Hans-Peter, Weidmann, Eckhart, von Gruenhagen, Ulrich, Mueller, Lothar, Sandherr, Michael, Hahn, Lars, Vereshchagina, Julia, Kauff, Frank, Blau, Wolfgang, Hinke, Axel, and Barth, Juergen

Published
2016
Full Text
View/download PDF

10. eTable 2 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Author

Stahler, Arndt, primary, Stintzing, Sebastian, primary, Modest, Dominik P., primary, Ricard, Ingrid, primary, Giessen-Jung, Clemens, primary, Kapaun, Christine, primary, Ivanova, Boryana, primary, Kaiser, Florian, primary, Fischer von Weikersthal, Ludwig, primary, Moosmann, Nicolas, primary, Schalhorn, Andreas, primary, Stauch, Martina, primary, Kiani, Alexander, primary, Held, Swantje, primary, Decker, Thomas, primary, Moehler, Markus, primary, Neumann, Jens, primary, Kirchner, Thomas, primary, Jung, Andreas, primary, and Heinemann, Volker, primary

Published
2023
Full Text
View/download PDF

11. eFigure 3 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Author

Stahler, Arndt, primary, Stintzing, Sebastian, primary, Modest, Dominik P., primary, Ricard, Ingrid, primary, Giessen-Jung, Clemens, primary, Kapaun, Christine, primary, Ivanova, Boryana, primary, Kaiser, Florian, primary, Fischer von Weikersthal, Ludwig, primary, Moosmann, Nicolas, primary, Schalhorn, Andreas, primary, Stauch, Martina, primary, Kiani, Alexander, primary, Held, Swantje, primary, Decker, Thomas, primary, Moehler, Markus, primary, Neumann, Jens, primary, Kirchner, Thomas, primary, Jung, Andreas, primary, and Heinemann, Volker, primary

Published
2023
Full Text
View/download PDF

12. eFigure 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Author

Stahler, Arndt, primary, Stintzing, Sebastian, primary, Modest, Dominik P., primary, Ricard, Ingrid, primary, Giessen-Jung, Clemens, primary, Kapaun, Christine, primary, Ivanova, Boryana, primary, Kaiser, Florian, primary, Fischer von Weikersthal, Ludwig, primary, Moosmann, Nicolas, primary, Schalhorn, Andreas, primary, Stauch, Martina, primary, Kiani, Alexander, primary, Held, Swantje, primary, Decker, Thomas, primary, Moehler, Markus, primary, Neumann, Jens, primary, Kirchner, Thomas, primary, Jung, Andreas, primary, and Heinemann, Volker, primary

Published
2023
Full Text
View/download PDF

13. eFigure 1 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Author

Stahler, Arndt, primary, Stintzing, Sebastian, primary, Modest, Dominik P., primary, Ricard, Ingrid, primary, Giessen-Jung, Clemens, primary, Kapaun, Christine, primary, Ivanova, Boryana, primary, Kaiser, Florian, primary, Fischer von Weikersthal, Ludwig, primary, Moosmann, Nicolas, primary, Schalhorn, Andreas, primary, Stauch, Martina, primary, Kiani, Alexander, primary, Held, Swantje, primary, Decker, Thomas, primary, Moehler, Markus, primary, Neumann, Jens, primary, Kirchner, Thomas, primary, Jung, Andreas, primary, and Heinemann, Volker, primary

Published
2023
Full Text
View/download PDF

14. Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Author

Meyer, Oliver, primary, Schlag, Rudolf, additional, Stauch, Thomas, additional, Fleischmann, Bastian, additional, Reiser, Marcel, additional, Kaempfe, Dietrich, additional, Behlendorf, Timo, additional, Welslau, Manfred, additional, von der Heyde, Eyck, additional, Dörfel, Steffen, additional, Willy, Claudia, additional, and Stauch, Martina, additional

Published
2022
Full Text
View/download PDF

15. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Author

Heinemann, Volker, von Weikersthal, Ludwig Fischer, Decker, Thomas, Kiani, Alexander, Vehling-Kaiser, Ursula, Al-Batran, Salah-Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Stauch, Martina, Scheithauer, Werner, Hielscher, Jörg, Scholz, Michael, Müller, Sebastian, Link, Hartmut, Niederle, Norbert, Rost, Andreas, Höffkes, Heinz-Gert, Moehler, Markus, Lindig, Reinhard U, Modest, Dominik P, Rossius, Lisa, Kirchner, Thomas, Jung, Andreas, and Stintzing, Sebastian

Published
2014
Full Text
View/download PDF

16. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.

Author

Stintzing, Sebastian, Heinrich, Kathrin, Tougeron, David, Modest, Dominik Paul, Schwaner, Ingo, Eucker, Jan, Pihusch, Rudolf, Stauch, Martina, Kaiser, Florian, Kahl, Christoph, Karthaus, Meinolf, Müller, Christian, Burkart, Christof, Reinacher-Schick, Anke, Kasper-Virchow, Stefan, Fischer von Weikersthal, Ludwig, Krammer-Steiner, Beate, Prager, Gerald Wolfgang, Taieb, Julien, and Heinemann, Volker

Published
2023
Full Text
View/download PDF

18. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Author

Eichhorst, Barbara F., Busch, Raymonde, Stilgenbauer, Stephan, Stauch, Martina, Bergmann, Manuela A., Ritgen, Matthias, Kranzhöfer, Nicole, Rohrberg, Robert, Söling, Ulrike, Burkhard, Oswald, Westermann, Anne, Goede, Valentin, Schweighofer, Carmen D., Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens M., Brittinger, Günter, Döhner, Hartmut, Emmerich, Bertold, and Hallek, Michael

Published
2009
Full Text
View/download PDF

19. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

Author

Al‐Batran, Salah‐Eddin, Hofheinz, Ralf‐Dieter, Reichart, Alexander, Pauligk, Claudia, Schönherr, Caroline, Schlag, Rudolf, Siegler, Gabriele, Dörfel, Steffen, Koenigsmann, Michael, Zahn, Mark‐Oliver, Schubert, Jörg, Aldaoud, Ali, Höffkes, Heinz‐Gert, Schulz, Holger, Hahn, Lars, Uhlig, Jens, Blau, Wolfgang, Stauch, Martina, Weniger, Jörg, Wolf, Martin, Jacobasch, Lutz, Bildat, Stephan, Wehmeyer, Jürgen, Homann, Nils, Trojan, Jörg, Waidmann, Oliver, Fietz, Thomas, Feustel, Hans‐Peter, Groschek, Matthias, Wierecky, Jan, Waibel, Karin, Mahlmann, Stefan, Schwindel, Uwe, Peters, Uwe, Schuch, Gunter, Pink, Daniel, Eschenburg, Henning, Wörns, Marcus‐A., Harich, Hans‐Detlev, Weikersthal, Ludwig Fischer, Däßler, Klaus‐Ulrich, Behringer, Dirk M., Messmann, Helmut, Kretzschmar, Albrecht, Gallmeier, Eike, Forstbauer, Helmut, Kunzmann, Volker, Papke, Jens, Büchner‐Steudel, Petra, Vehling‐Kaiser, Ursula, Springfeld, Christoph, Vogel, Arndt, Ettrich, Thomas J., Schaaf, Marina, Hausen, Gerrit zur, and Götze, Thorsten Oliver

Published
2021

20. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia

Author

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael

Abstract

Observation is the current standard of care for patients with early-stage asymptomatic chronic lymphocytic leukemia (CLL), as chemotherapy-based interventions have failed to prolong survival. We hypothesized that early intervention with ibrutinib would be well tolerated and lead to superior disease control in a subgroup of early-stage patients with CLL. The phase 3, double-blind, placebo-controlled CLL12 trial randomly assigned asymptomatic, treatment-naive Binet stage A CLL patients at increased risk of progression in a 1:1 ratio to receive ibrutinib (n = 182) or placebo (n = 181) at a dose of 420 mg daily. At a median follow-up of 31 months, the study met its primary endpoint by significantly improv-ing event-free survival in the ibrutinib group (median, not reached vs 47.8 months; hazard ratio = 0.25; 95% confidence interval = 0.14-0.43, P < .0001). Compared with placebo, ibrutinib did not increase overall toxicity, yielding similar incidence and severity of adverse events (AEs). The most common serious AEs were atrial fibrillation, pneumonia, and rash in the ibrutinib group, and basal cell carcinoma, pneumonia, and myocardial infarction in the placebo group. Ibrutinib-associated risk for bleeding (33.5%) was decreased by prohibiting the use of oral anticoagulants through an amendment of the study protocol and by avoiding CYP3A4 drug-drug interactions. Ibrutinib confirms efficacy in CLL patients at an early stage with an increased risk of progression. However, the results do not justify changing the current stan-dard of watch and wait.

Published
2021

22. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

Author

Stintzing, Sebastian, primary, Heinrich, Kathrin, additional, Tougeron, David, additional, Modest, Dominik Paul, additional, Schwaner, Ingo, additional, Euker, Jan, additional, Pihusch, Rudolf, additional, Stauch, Martina, additional, Kaiser, Florian, additional, Kahl, Christoph, additional, Karthaus, Meinolf, additional, Mueller, Christian, additional, Burkart, Christof, additional, Reinacher-Schick, Anke C., additional, Kasper, Stefan, additional, Fischer von Weikersthal, Ludwig, additional, Krammer-Steiner, Beate, additional, Prager, Gerald W., additional, Taieb, Julien, additional, and Heinemann, Volker, additional

Published
2021
Full Text
View/download PDF

23. Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial

Author

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Gerwin, Henrik, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael J., Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Gerwin, Henrik, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael J., Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael

Published
2020

24. Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Author

Stahler, Arndt, primary, Stintzing, Sebastian, additional, Modest, Dominik P., additional, Ricard, Ingrid, additional, Giessen-Jung, Clemens, additional, Kapaun, Christine, additional, Ivanova, Boryana, additional, Kaiser, Florian, additional, Fischer von Weikersthal, Ludwig, additional, Moosmann, Nicolas, additional, Schalhorn, Andreas, additional, Stauch, Martina, additional, Kiani, Alexander, additional, Held, Swantje, additional, Decker, Thomas, additional, Moehler, Markus, additional, Neumann, Jens, additional, Kirchner, Thomas, additional, Jung, Andreas, additional, and Heinemann, Volker, additional

Published
2020
Full Text
View/download PDF

25. Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3rd Interim Analysis of the German Non-Interventional Trial RISA

Author

Meyer, Oliver, primary, Stauch, Martina, additional, Kaempfe, Dietrich, additional, Schlag, Rudolf, additional, Reiser, Marcel, additional, von der Heyde, Eyck, additional, Josting, Andreas, additional, Plath, Margarete, additional, Ballerstädt, Nadine, additional, Stark-Lorenzen, Petra, additional, and Matzdorff, Axel, additional

Published
2020
Full Text
View/download PDF

26. Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study.

Author

von Einem, Jobst C., primary, Stintzing, Sebastian, additional, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmuller, Christian A., additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Hielscher, Joerg, additional, Scholz, Michael, additional, Modest, Dominik Paul, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2020
Full Text
View/download PDF

27. High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.

Author

Stahler, Arndt, primary, Stintzing, Sebastian, additional, Modest, Dominik Paul, additional, Ricard, Ingrid, additional, Kapaun, Christine, additional, Ivanova, Boryana, additional, Vehling-Kaiser, Ursula, additional, Fischer von Weikersthal, Ludwig, additional, Schalhorn, Andreas, additional, Stauch, Martina, additional, Kiani, Alexander, additional, Neumann, Jens, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2020
Full Text
View/download PDF

30. Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

Author

John Matthias, Hinke Axel, Stauch Martina, Wolf Heiner, Mohr Benno, Hindenburg Hans-Joachim, Papke Jens, and Schlosser Joachim

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the palliative setting. The present trial examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients. Methods Patients with histologically confirmed metastatic breast cancer overexpressing HER2 were eligible if pretreated with anthracycline in either the adjuvant or palliative setting. Treatment consisted of weekly trastuzumab (2 mg/kg/week for up to one year after a loading dose of 4 mg/kg in week 1) and paclitaxel (90 mg/m², administered in weeks 1–6 and 8–13). Results Twenty-seven German centers enrolled 121 patients. The median number of metastatic sites was two (range 1–5); 38% of patients had received chemotherapy for advanced disease. After a median 42 weeks of trastuzumab treatment, limited by disease progression in roughly half the patients, a best objective response rate (complete response + partial response) of 76% was achieved, including complete remissions in 29%. 74% of patients lived without tumor progression at six months. Median progression-free and overall survival were 9.4 (95% confidence interval [CI]: 8.1–11.3) and 22 months (95% CI: 17–46). After alopecia, Common Toxicity Criteria grade ≥2 toxicity was predominantly hematological (leukopenia [31%] and anemia [41%]); however, thrombocytopenia occurred in only 5%. Neurotoxicity was remarkably low. Two cardiac events (grades 2 and 3) were presumed treatment-related. Conclusions Weekly paclitaxel plus trastuzumab allows an increased dose density and offers an attractive and effective alternative to the conventional schedule. Limiting the duration of cytotoxic therapy to 3 months seems to be an option to reduce neurotoxicity without impairing long-term outcome.

Published
2012
Full Text
View/download PDF

31. Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).

Author

Heinemann, Volker, primary, Modest, Dominik Paul, additional, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Kaiser, Florian, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmuller, Christian A., additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Held, Swantje, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Stintzing, Sebastian, additional

Published
2019
Full Text
View/download PDF

32. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Emile, Jean-François, primary, Julié, Catherine, additional, Le Malicot, Karine, additional, Lepage, Come, additional, Tabernero, Josep, additional, Mini, Enrico, additional, Folprecht, Gunnar, additional, Van Laethem, Jean-Luc, additional, Dimet, Stéphanie, additional, Boulagnon-Rombi, Camille, additional, Allard, Marc-Antoine, additional, Penault-Llorca, Frédérique, additional, Bennouna, Jaafar, additional, Laurent-Puig, Pierre, additional, Taieb, Julien, additional, Thaler, Josef, additional, Greil, Richard, additional, Gaenzer, Johannes, additional, Eisterer, Wolfgang, additional, Tschmelitsch, Joerg, additional, Keil, Felix, additional, Samonigg, Hellmut, additional, Zabernigg, August, additional, Schmid, Franz, additional, Steger, Günther, additional, Steinacher, Robert, additional, Andel, Johannes, additional, Jagdt, Björn, additional, Lang, Alois, additional, Fridrik, Michael, additional, Függer, Reinhold, additional, Hofbauer, Friedrich, additional, Woell, Ewald, additional, Geissler, Dietmar, additional, Lenauer, Alfred, additional, Prager, Manfred, additional, D'Haens, Geert, additional, Demolin, Gauthier, additional, Kerger, Joseph, additional, Deboever, Guido, additional, Ghillebert, Gilbert, additional, Polus, Marc, additional, Van Cutsem, Eric, additional, Kalantari, Hassan Rezaie, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles, additional, Peeters, Marc, additional, Vergauwe, Philippe, additional, Houbiers, Ghislain, additional, Humblet, Yves, additional, Janssens, Jos, additional, Schrijvers, Dirk, additional, Vanderstraeten, Erik, additional, Vermorken, Jan, additional, Van Daele, Daniel, additional, Ferrante, Michel, additional, Forget, Frederic, additional, Hendlisz, Alain, additional, Yilmaz, Mette, additional, Nielsen, Svend Erik, additional, Vestermark, Lene, additional, Larsen, Jim, additional, Zawadi, Mohamed-Ayman, additional, Bouche, Olivier, additional, Mineur, Laurent, additional, Bennouna-Louridi, Jaafar, additional, Dourthe, Louis Marie, additional, Ychou, Marc, additional, Boucher, Eveline, additional, Pezet, Denis, additional, Desseigne, Francoise, additional, Ducreux, Michel, additional, Texereau, Patrick, additional, Miglianico, Laurent, additional, Rougier, Philippe, additional, Fratte, Serge, additional, Levache, Charles-Briac, additional, Merrouche, Yacine, additional, Ellis, Stephen, additional, Locher, Christophe, additional, Ramee, Jean-Francois, additional, Garnier, Claire, additional, Viret, Frederic, additional, Chauffert, Bruno, additional, Cojean-Zelek, Isabelle, additional, Michel, Pierre, additional, Lecaille, Cedric, additional, Borel, Christian, additional, Seitz, Jean-Francois, additional, Smith, Denis, additional, Lombard-Bohas, Catherine, additional, Andre, Thierry, additional, Gornet, Jean-Marc, additional, Fein, Francine, additional, Coulon-Sfairi, Marie-Aude, additional, Kaminsky, Marie-Christine, additional, Lagasse, Jean-Paul, additional, Luet, Dominique, additional, Etienne, Pierre-Luc, additional, Gasmi, Mohamed, additional, Vanoli, Andre, additional, Nguyen, Suzanne, additional, Aparicio, Thomas, additional, Perrier, Hervé, additional, Stremsdoerfer, Noel, additional, Laplaige, Philippe, additional, Arsene, Dominique, additional, Auby, Dominique, additional, Bedenne, Laurent, additional, Coriat, Romain, additional, Denis, Bernard, additional, Geoffroy, Patrick, additional, Piot, Gilles, additional, Becouarn, Yves, additional, Bordes, Gilbert, additional, Deplanque, Gael, additional, Dupuis, Olivier, additional, Fruge, Frederic, additional, Guimbaud, Rosine, additional, Lecomte, Thierry, additional, Lledo, Gérard, additional, Sobhani, Iradej, additional, Asnacios, Amani, additional, Azzedine, Ahmed, additional, Desauw, Christophe, additional, Galais, Marie-Pierre, additional, Gargot, Dany, additional, Lam, You-Heng, additional, Abakar-Mahamat, Abakar, additional, Berdah, Jean-Francois, additional, Catteau, Sylviane, additional, Clavero-Fabri, Marie-Christine, additional, Codoul, Jean-Francois, additional, Legoux, Jean-Louis, additional, Goldfain, Denis, additional, Guichard, Pierre, additional, Verge, Denis Pere, additional, Provencal, Jocelyne, additional, Vedrenne, Bruno, additional, Brezault-Bonnet, Catherine, additional, Cleau, Denis, additional, Desir, Jean-Paul, additional, Fallik, David, additional, Garcia, Bruno, additional, Gaspard, Marie-Hélène, additional, Genet, Dominique, additional, Hartwig, Johannes, additional, Krummel, Yves, additional, Budnik, Tamara Matysiak, additional, Palascak-Juif, Vanessa, additional, Randrianarivelo, Harizo, additional, Rinaldi, Yves, additional, Aleba, Albert, additional, Darut-Jouve, Ariane, additional, de Gramont, Aimery, additional, Hamon, Herve, additional, Wendehenne, Frederic, additional, Matzdorff, Axel, additional, Stahl, Michael Konrad, additional, Schepp, Wolfgang, additional, Burk, Martin, additional, Mueller, Lothar, additional, Geissler, Michael, additional, Mantovani-Loeffler, Luisa, additional, Hoehler, Thomas, additional, Asperger, Walter, additional, Kroening, Hendrik, additional, von Weikersthal, Ludwig Fischer, additional, Fuxius, Stefan, additional, Groschek, Matthias, additional, Meiler, Johannes, additional, Trarbach, Tanja, additional, Rauh, Jacqueline, additional, Ziegenhagen, Nicolas, additional, Kretzschmar, Albrecht, additional, Graeven, Ullrich, additional, Nusch, Arnd, additional, von Wichert, Goetz, additional, Hofheinz, Ralf-Dieter, additional, Kleber, Gerhard, additional, Schmidt, Karl-Heinz, additional, Vehling-Kaiser, Ursula, additional, Baum, Claudia, additional, Schuette, Jochen, additional, Haag, Georg Martin, additional, Holtkamp, Wilhelm, additional, Potenberg, Jochen, additional, Reiber, Tobias, additional, Schliesser, Georg, additional, Schmoll, Hans-Joachim, additional, Schneider-Kappus, Wolfgang, additional, Abenhardt, Wolfgang, additional, Denzlinger, Claudio, additional, Henning, Jan, additional, Marxsen, Bartscht, additional, Derigs, Hans Guenter, additional, Lambertz, Helmut, additional, Becker-Boost, Ingulf, additional, Caca, Karel, additional, Constantin, Christian, additional, Decker, Thomas, additional, Eschenburg, Henning, additional, Gabius, Sigrun, additional, Hebart, Holger, additional, Hoffmeister, Albrecht, additional, Horst, Heinz-August, additional, Kremers, Stephan, additional, Leithaeuser, Malte, additional, Mueller, Sebastian, additional, Wagner, Siegfried, additional, Daum, Severin, additional, Schlegel, Frank, additional, Stauch, Martina, additional, Heinemann, Volker, additional, Maiello, Evaristo, additional, Latini, Luciano, additional, Zaniboni, Alberto, additional, Amadori, Dino, additional, Aprile, Giuseppe, additional, Barni, Sandro, additional, Mattioli, Rodolfo, additional, Martoni, Andrea, additional, Passalacqua, Rodolfo, additional, Nicolini, Mario, additional, Pasquini, Enzo, additional, Rabbi, Carla, additional, Aitini, Enrico, additional, Ravaioli, Alberto, additional, Barone, Carlo, additional, Biasco, Guido, additional, Tamberi, Stefano, additional, Gambi, Angelo, additional, Verusio, Claudio, additional, Marzola, Marina, additional, Lelli, Giorgio, additional, Boni, Corrado, additional, Cascinu, Stefano, additional, Bidoli, Paolo, additional, Vaghi, Massimo, additional, Cruciani, Giorgio, additional, Di Costanzo, Francesco, additional, Sobrero, Alberto, additional, Petrioli, Roberto, additional, Aglietta, Massimo, additional, Alabiso, Oscar, additional, Capuzzo, Federico, additional, Falcone, Alfredo, additional, Corsi, Domenico Cristi, additional, Labianca, Roberto, additional, Salvagni, Stefania, additional, Chiara, Silvana, additional, Ciuffreda, Libero, additional, Ferraù, Francesco, additional, Giuliani, Francesco, additional, Lonardi, Sara, additional, Gebbia, Nicola, additional, Mantovani, Giovanni, additional, Sanches, Evaristo, additional, Mellidez, Juan Carlos, additional, Santos, Pedro, additional, Freire, Joao, additional, Sarmento, Cristina, additional, Costa, Luis, additional, Pinto, Antonio Moreira, additional, Barroso, Sergio, additional, Santo, Jorge Espirito, additional, Guedes, Fátima, additional, Monteiro, Amélia, additional, Sa, Anabela, additional, Furtado, Irene, additional, Salazar, Ramon, additional, Aguilar, Enrique Aranda, additional, Herrero, Fernando Rivera, additional, Valera, Javier Sastre, additional, Ayerbes, Manuel Valladares, additional, Batlle, Jaime Feliu, additional, Gil, Silvia, additional, Esteve, Albert Abad, additional, Garcia-Giron, Carlos, additional, Vivanco, Guillermo Lopez, additional, Salvia, Antonia Salud, additional, Orduña, Vicente Alonso, additional, Garcia, Ruth Vera, additional, Gallego, Javier, additional, Sureda, Bartomeu Massuti, additional, Remon, Jordi, additional, Safont Aguilera, Maria Jose, additional, Nogueras, Luis Cirera, additional, Merino, Bernado Queralt, additional, Castro, Cristina Gravalos, additional, de Prado, Purificacion Martinez, additional, Pericay, Carlos Pijaume, additional, Figueiras, Manuel Constenla, additional, Jordan, Inmaculada Guasch, additional, Gome Reina, Maria Jose, additional, Garcia, Amelia Lopez-Ladron, additional, Garcia-Ramos, Antonio Arrivi, additional, Cervantes, Andres, additional, Martos, Carlos Fernandez, additional, Gaspar, Eugenio Marcuello, additional, Montero, Ines Cabezas, additional, Emperador, Pilar Escudero, additional, Carbonero, Ana Leon, additional, Castillo, Manuel Gallen, additional, Garcia, Teresa Garcia, additional, Lopez, Jose Garcia, additional, Flores, Encarnacion Gonzalez, additional, Morales, Monica Guillot, additional, Muñoz, Marta Llanos, additional, Martín, Ana López, additional, Maurel, Joan, additional, Camara, Juan Carlos, additional, Garcia, Rosario Dueñas, additional, Salgado, Mercedes, additional, Busquier, Isabel Hernandez, additional, Ruiz, Teresa Checa, additional, Muñoa, Adelaida Lacasta, additional, Aliguer, Miquel Nogue, additional, de Taranco, Amalia Velasco Ortiz, additional, Ureña, Miguel Mendez, additional, Gaspa, Ferran Losa, additional, Ponce, Jose Juan, additional, Roig, Carlos Bosch, additional, Jimenez, Pedro Valero, additional, Brotons, Antonio Galan, additional, Rodriguez, Santiago Albiol, additional, Martinez, Jose Ales, additional, Ruiz, Liliana Canosa, additional, Ruiz, Margarita Centelles, additional, Bridgewater, John, additional, Glynne-Jones, Rob, additional, Tahir, Saad, additional, Hickish, Tamas, additional, Cassidy, Jim, additional, and Samuel, Leslie, additional

Published
2017
Full Text
View/download PDF

33. Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

Author

Stahler, Arndt, primary, Heinemann, Volker, additional, Neumann, Jens, additional, Crispin, Alexander, additional, Schalhorn, Andreas, additional, Stintzing, Sebastian, additional, Giessen-Jung, Clemens, additional, Fischer von Weikersthal, Ludwig, additional, Vehling-Kaiser, Ursula, additional, Stauch, Martina, additional, Quietzsch, Detlef, additional, Holch, Julian W., additional, Kruger, Stephan, additional, Haas, Michael, additional, Michl, Marlies, additional, von Einem, Jobst, additional, Kirchner, Thomas, additional, Jung, Andreas, additional, and Modest, Dominik P., additional

Published
2017
Full Text
View/download PDF

34. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

Author

Rummel, Mathias J., primary, Maschmeyer, Georg, additional, Ganser, Arnold, additional, Heider, Andrea, additional, von Gruenhagen, Ulrich, additional, Losem, Christoph, additional, Heil, Gerhard, additional, Welslau, Manfred, additional, Balser, Christina, additional, Kaiser, Ulrich, additional, Weidmann, Eckhart, additional, Dürk, Heinz Albert, additional, Ballo, Harald, additional, Stauch, Martina, additional, Blau, Wolfgang, additional, Burchardt, Alexander, additional, Barth, Juergen, additional, Kauff, Frank, additional, and Brugger, Wolfram, additional

Published
2017
Full Text
View/download PDF

35. Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

Author

Modest, Dominik Paul, primary, Stintzing, Sebastian, additional, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Held, Swantje, additional, Giessen-Jung, Clemens, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2017
Full Text
View/download PDF

36. Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306).

Author

Modest, Dominik Paul, primary, Ricard, Ingrid, additional, Stintzing, Sebastian, additional, Fischer von Weikersthal, Ludwig, additional, Sobrero, Alberto F., additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmuller, Christian A., additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Moehler, Markus H., additional, Held, Swantje, additional, and Heinemann, Volker, additional

Published
2016
Full Text
View/download PDF

37. Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

Author

zur Hausen, Gerrit, primary, Waidmann, Oliver, additional, Woerns, Marcus A., additional, Hoeffkes, Heinz-Gert, additional, Doerfel, Steffen, additional, Zahn, Mark-Oliver, additional, Aldaoud, Ali, additional, Stauch, Martina, additional, Springfeld, Christoph, additional, Haertel, Nicolai, additional, Reichart, Alexander, additional, Pauligk, Claudia, additional, Roemmler-Zehrer, Josefine, additional, Hofheinz, Ralf, additional, and Al-Batran, Salah-Eddin, additional

Published
2016
Full Text
View/download PDF

38. Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).

Author

Modest, Dominik Paul, primary, Stintzing, Sebastian, additional, Fischer von Weikersthal, Ludwig, additional, Sobrero, Alberto F., additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Seipelt, Gernot, additional, Lerchenmuller, Christian A., additional, Kahl, Christoph, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Held, Swantje, additional, Moehler, Markus H., additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2016
Full Text
View/download PDF

39. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)

Author

Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Doehner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael, Eichhorst, Barbara, Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Doehner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael, and Eichhorst, Barbara

Abstract

To evaluate the effect of first-line and subsequent therapies, the outcome of 1,558 patients with chronic lymphocytic leukemia from five prospective phase II/III trials conducted between 1999 and 2010 was analyzed. The 3-year overall survival rate was higher after first-line treatment with chemoimmunotherapies such as fludarabine/cyclophosphamide/rituximab (87.9%) or bendamustine/rituximab (90.7%) compared to chemotherapies without an antibody (fludarabine/cyclophosphamide: 84.6%; fludarabine: 77.5%; chlorambucil: 77.4%). Furthermore, the median overall survival was longer in patients receiving at least one antibody-containing regimen in any treatment line (94.4 months) compared to the survival in patients who never received an antibody (84.3 months, P<0.0001). Univariate Cox regression analysis demonstrated that patients who did not receive antibody treatment had a 1.42-fold higher risk of death (hazard ratio, 1.42; 95% confidence interval: 1.185-1.694). Therapies administered at relapse were very heterogeneous. Only 55 of 368 patients (14.9%) who started second-line treatment > 24 months after first-line therapy repeated the first-line regimen. Among 315 patients requiring treatment <= 24 months after first-line therapy, cyclophosphamide/doxorubicin/vincristine/prednisone with or without rituximab as well as alemtuzumab were the most commonly used therapies. In these early relapsing patients, the median overall survival was shorter following therapies containing an anthracycline and/or three or more cytotoxic agents (e.g. cyclophosphamide/doxorubicin/vincristine/prednisone or fludarabine/cyclophosphamide/mitoxantrone, 30.0 months) compared to single agent chemotherapy (e.g. fludarabine; 39.6 months) and standard chemoimmunotherapy (e.g. fludarabine/cyclophosphamide/rituximab: 61.6 months). In conclusion, the analysis confirms the superior efficacy of chemoimmunotherapies in patients with chronic lymphocytic leukemia. Moreover, the use of aggressive chemo(immuno) t

Published
2015

40. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Author

Modest, Dominik P., primary, Stintzing, Sebastian, additional, von Weikersthal, Ludwig Fischer, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmüller, Christian, additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Held, Svantje, additional, Möhler, Markus, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2015
Full Text
View/download PDF

41. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

Author

Pelzer, Uwe, primary, Opitz, Bernhard, additional, Deutschinoff, Gerd, additional, Stauch, Martina, additional, Reitzig, Peter C., additional, Hahnfeld, Sabine, additional, Müller, Lothar, additional, Grunewald, Martina, additional, Stieler, Jens M., additional, Sinn, Marianne, additional, Denecke, Timm, additional, Bischoff, Sven, additional, Oettle, Helmut, additional, Dörken, Bernd, additional, and Riess, Hanno, additional

Published
2015
Full Text
View/download PDF

42. Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).

Author

Michl, Marlies, primary, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmueller, Christian, additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Hielscher, Joerg, additional, Scholz, Michael, additional, Modest, Dominik Paul, additional, Stintzing, Sebastian, additional, Kirchner, Thomas, additional, Jung, Andreas, additional, and Heinemann, Volker, additional

Published
2015
Full Text
View/download PDF

43. Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study.

Author

Stintzing, Sebastian, primary, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmueller, Christian, additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Hielscher, Carsten, additional, Held, Swantje, additional, Modest, Dominik Paul, additional, Moehler, Markus H., additional, Scheithauer, Werner, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2015
Full Text
View/download PDF

44. Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3- expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.

Author

Stahler, Arndt, primary, Heinemann, Volker, additional, Giessen, Clemens Albrecht, additional, Schalhorn, Andreas, additional, Stintzing, Sebastian, additional, Fischer von Weikersthal, Ludwig, additional, Vehling-Kaiser, Ursula, additional, Stauch, Martina, additional, Quietzsch, Detlef, additional, Neumann, Jens, additional, Kirchner, Thomas, additional, Jung, Andreas, additional, and Modest, Dominik Paul, additional

Published
2015
Full Text
View/download PDF

45. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Author

Thaler, Josef, primary, Greil, Richard, additional, Gaenzer, Johannes, additional, Eisterer, Wolfgang, additional, Tschmelitsch, Joerg, additional, Samonigg, Hellmut, additional, Zabernigg, August, additional, Schmid, Franz, additional, Steger, Günther, additional, Steinacher, Robert, additional, Andel, Johannes, additional, Lang, Alois, additional, Függer, Reinhold, additional, Hofbauer, Friedrich, additional, Woell, Ewald, additional, Geissler, Dietmar, additional, Lenauer, Alfred, additional, Prager, Manfred, additional, Van Laethem, Jean-Luc, additional, Van Cutsem, Eric, additional, D'Haens, Geert, additional, Demolin, Gauthier, additional, Kerger, Joseph, additional, Deboever, Guido, additional, Ghillebert, Gilbert, additional, Polus, Marc, additional, RezaieKalantari, Hassan, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles, additional, Peeters, Marc, additional, Vergauwe, Philippe, additional, Houbiers, Ghislain, additional, Humblet, Yves, additional, Janssens, Jos, additional, Schrijvers, Dirk, additional, Vanderstraeten, Erik, additional, Vermorken, Jan, additional, Van Daele, Daniel, additional, Ferrante, Michel, additional, Forget, Frederic, additional, Hendlisz, Alain, additional, Yilmaz, Mette, additional, Nielsen, Svend Erik, additional, Vestermark, Lene, additional, Larsen, Jim, additional, Ychou, Marc, additional, Zawadi, Ayman, additional, Zawadi, Mohamed-Ayman, additional, Bouche, Olivier, additional, Mineur, Laurent, additional, Bennouna-Louridi, Jaafar, additional, Dourthe, Louis Marie, additional, Boucher, Eveline, additional, Taieb, Julien, additional, Pezet, Denis, additional, Desseigne, Francoise, additional, Ducreux, Michel, additional, Texereau, Patrick, additional, Miglianico, Laurent, additional, Rougier, Philippe, additional, Fratte, Serge, additional, Levache, Charles-Briac, additional, Merrouche,, Yacine, additional, Ellis, Stephen, additional, Locher, Christophe, additional, Ramee, Jean-Francois, additional, Garnier, Claire, additional, Viret, Frederic, additional, Chauffert, Bruno, additional, Cojean-Zelek, Isabelle, additional, Michel, Pierre, additional, Lecaille, Cedric, additional, Borel, Christian, additional, Seitz, Jean-Francois, additional, Smith, Denis, additional, Lombard-Bohas, Catherine, additional, Andre, Thierry, additional, Gornet, Jean-Marc, additional, Fein, Francine, additional, Coulon-Sfairi, Marie-Aude, additional, Kaminsky, Marie-Christine, additional, Lagasse, Jean-Paul, additional, Luet, Dominique, additional, Etienne, Pierre-Luc, additional, Gasmi, Mohamed, additional, Vanoli, Andre, additional, Nguyen, Suzanne, additional, Aparicio, Thomas, additional, Perrier, Hervé, additional, Stremsdoerfer, Noel, additional, Laplaige, Philippe, additional, Arsene, Dominique, additional, Auby, Dominique, additional, Bedenne, Laurent, additional, Coriat, Romain, additional, Denis, Bernard, additional, Geoffroy, Patrick, additional, Piot, Gilles, additional, Becouarn, Yves, additional, Bordes, Gilbert, additional, Deplanque, Gael, additional, Dupuis, Olivier, additional, Fruge, Frederic, additional, Guimbaud, Rosine, additional, Lecomte, Thierry, additional, Lledo, Gérard, additional, Sobhani, Iradej, additional, Asnacios, Amani, additional, Azzedine, Ahmed, additional, Desauw, Christophe, additional, Galais, Marie-Pierre, additional, Gargot, Dany, additional, Lam, You-Heng, additional, Abakar-Mahamat, Abakar, additional, Berdah, Jean-Francois, additional, Catteau, Sylviane, additional, Clavero-Fabri, Marie-Christine, additional, Codoul, Jean-Francois, additional, Legoux, Jean-Louis, additional, Goldfain, Denis, additional, Guichard, Pierre, additional, Verge, Denis Pere, additional, Provencal, Jocelyne, additional, Vedrenne, Bruno, additional, Brezault-Bonnet, Catherine, additional, Cleau, Denis, additional, Desir, Jean-Paul, additional, Fallik, David, additional, Garcia, Bruno, additional, Gaspard, Marie-Hélène, additional, Genet, Dominique, additional, Hartwig, Johannes, additional, Krummel, Yves, additional, MatysiakBudnik, Tamara, additional, Palascak-Juif, Vanessa, additional, Randrianarivelo, Harizo, additional, Rinaldi, Yves, additional, Aleba, Albert, additional, Darut-Jouve, Ariane, additional, de Gramont, Aimery, additional, Hamon, Herve, additional, Wendehenne, Frederic, additional, Matzdorff, Axel, additional, Stahl, Michael Konrad, additional, Schepp, Wolfgang, additional, Burk, Martin, additional, Mueller, Lothar, additional, Folprecht, Gunnar, additional, Geissler, Michael, additional, Mantovani-Loeffler, Luisa, additional, Hoehler, Thomas, additional, Asperger, Walter, additional, Kroening, Hendrik, additional, von Weikersthal, Ludwig Fischer, additional, Fuxius, Stefan, additional, Groschek, Matthias, additional, Meiler, Johannes, additional, Trarbach, Tanja, additional, Rauh, Jacqueline, additional, Ziegenhagen, Nicolas, additional, Kretzschmar, Albrecht, additional, Graeven, Ullrich, additional, Nusch, Arnd, additional, von Wichert, Goetz, additional, Hofheinz, Ralf-Dieter, additional, Kleber, Gerhard, additional, Schmidt, Karl-Heinz, additional, Vehling-Kaiser, Ursula, additional, Baum, Claudia, additional, Schuette, Jochen, additional, Haag, Georg Martin, additional, Holtkamp, Wilhelm, additional, Potenberg, Jochen, additional, Reiber, Tobias, additional, Schliesser, Georg, additional, Schmoll, Hans-Joachim, additional, Schneider-Kappus, Wolfgang, additional, Abenhardt, Wolfgang, additional, Denzlinger, Claudio, additional, Henning, Jan, additional, Marxsen, Bartscht, additional, GuenterDerigs, Hans, additional, Lambertz, Helmut, additional, Becker-Boost, Ingulf, additional, Caca, Karel, additional, Constantin, Christian, additional, Decker, Thomas, additional, Eschenburg, Henning, additional, Gabius, Sigrun, additional, Hebart, Holger, additional, Hoffmeister, Albrecht, additional, Horst, Heinz-August, additional, Kremers, Stephan, additional, Leithaeuser, Malte, additional, Mueller, Sebastian, additional, Wagner, Siegfried, additional, Daum, Severin, additional, Schlegel, Frank, additional, Stauch, Martina, additional, Heinemann, Volker, additional, Labianca, Roberto, additional, Colucci, Giuseppe, additional, Amadori, Dino, additional, Mini, Enrico, additional, Falcone, Alfredo, additional, Boni, Corrado, additional, Maiello, Evaristo, additional, Latini, Luciano, additional, Zaniboni, Alberto, additional, Aprile, Giuseppe, additional, Barni, Sandro, additional, Mattioli, Rodolfo, additional, Martoni, Andrea, additional, Passalacqua, Rodolfo, additional, Nicolini, Mario, additional, Pasquini, Enzo, additional, Rabbi, Carla, additional, Aitini, Enrico, additional, Ravaioli, Alberto, additional, Barone, Carlo, additional, Biasco, Guido, additional, Tamberi, Stefano, additional, Gambi, Angelo, additional, Verusio, Claudio, additional, Marzola, Marina, additional, Lelli, Giorgio, additional, Cascinu, Stefano, additional, Bidoli, Paolo, additional, Vaghi, Massimo, additional, Cruciani, Giorgio, additional, Di Costanzo, Francesco, additional, Sobrero, Alberto, additional, Petrioli, Roberto, additional, Aglietta, Massimo, additional, Alabiso, Oscar, additional, Capuzzo, Federico, additional, Corsi, Domenico Cristi, additional, Salvagni, Stefania, additional, Chiara, Silvana, additional, Ferraù, Francesco, additional, Giuliani, Francesco, additional, Lonardi, Sara, additional, Gebbia, Nicola, additional, Mantovani, Giovanni, additional, Sanches, Evaristo, additional, Mellidez, Juan Carlos, additional, Santos, Pedro, additional, Freire, Joao, additional, Sarmento, Cristina, additional, Costa, Luis, additional, Pinto, Antonio Moreira, additional, Barroso, Sergio, additional, Santo, Jorge Espirito, additional, Guedes, Fátima, additional, Monteiro, Amélia, additional, Sa, Anabela, additional, Furtado, Irene, additional, Tabernero, Josep, additional, Salazar, Ramon, additional, Aguilar, Enrique Aranda, additional, Herrero, Fernando Rivera, additional, Valera, Javier Sastre, additional, ValladaresAyerbes, Manuel, additional, FeliuBatlle, Jaime, additional, Gil, Silvia, additional, Garcia-Giron, Carlos, additional, Vivanco, Guillermo Lopez, additional, Salvia, Antonia Salud, additional, Orduña, Vicente Alonso, additional, Garcia, Ruth Vera, additional, Gallego, Javier, additional, Sureda, Bartomeu Massuti, additional, Remon, Jordi, additional, Safont Aguilera, Maria Jose, additional, CireraNogueras, Luis, additional, Merino, BernadoQueralt, additional, Castro, Cristina Gravalos, additional, de Prado, Purificacion Martinez, additional, PijaumePericay, Carlos, additional, ConstenlaFigueiras, Manuel, additional, Jordan, InmaculadaGuasch, additional, GomeReina, Maria Jose, additional, Garcia, Amelia Lopez-Ladron, additional, Garcia-Ramos, Antonio Arrivi, additional, Cervantes, Andres, additional, Martos, Carlos Fernandez, additional, MarcuelloGaspar, Eugenio, additional, Montero, Ines Cabezas, additional, Emperador, Pilar Escudero, additional, Carbonero, Ana Leon, additional, Castillo, Manuel Gallen, additional, Garcia, Teresa Garcia, additional, Lopez, Jose Garcia, additional, Flores, Encarnacion Gonzalez, additional, GuillotMorales, Monica, additional, LlanosMuñoz, Marta, additional, Martín, Ana López, additional, Maurel, Joan, additional, Camara, Juan Carlos, additional, Garcia, Rosario Dueñas, additional, Salgado, Mercedes, additional, HernandezBusquier, Isabel, additional, Ruiz, Teresa Checa, additional, LacastaMuñoa, Adelaida, additional, Aliguer, MiquelNogue, additional, Ortiz de Taranco, Amalia Velasco, additional, Ureña, Miguel Mendez, additional, Gaspa, Ferran Losa, additional, Ponce, Jose Juan, additional, Roig, Carlos Bosch, additional, Jimenez, Pedro Valero, additional, GalanBrotons, Antonio, additional, AlbiolRodriguez, Santiago, additional, Martinez, Jose Ales, additional, Ruiz, Liliana Canosa, additional, CentellesRuiz, Margarita, additional, Bridgewater, John, additional, Glynne-Jones, Rob, additional, Tahir, Saad, additional, Hickish, Tamas, additional, Cassidy, Jim, additional, and Samuel, Leslie, additional

Published
2015
Full Text
View/download PDF

46. Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Author

Stintzing, Sebastian, primary, Modest, Dominik Paul, additional, Fischer von Weikersthal, Ludwig, additional, Decker, Thomas, additional, Kiani, Alexander, additional, Vehling-Kaiser, Ursula, additional, Al-Batran, Salah-Eddin, additional, Heintges, Tobias, additional, Lerchenmuller, Christian A., additional, Kahl, Christoph, additional, Seipelt, Gernot, additional, Kullmann, Frank, additional, Stauch, Martina, additional, Scheithauer, Werner, additional, Held, Swantje, additional, Giessen, Clemens Albrecht, additional, Moehler, Markus Hermann, additional, Jung, Andreas, additional, Kirchner, Thomas, additional, and Heinemann, Volker, additional

Published
2015
Full Text
View/download PDF

47. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

Author

Goede, Valentin, Cramer, Paula, Busch, Raymonde, Bergmann, Manuela, Stauch, Martina, Hopfinger, Georg, Stilgenbauer, Stephan, Doehner, Hartmut, Westermann, Anne, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael, Goede, Valentin, Cramer, Paula, Busch, Raymonde, Bergmann, Manuela, Stauch, Martina, Hopfinger, Georg, Stilgenbauer, Stephan, Doehner, Hartmut, Westermann, Anne, Wendtner, Clemens M., Eichhorst, Barbara, and Hallek, Michael

Abstract

This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. Patients with two or more comorbidities and patients with less than two comorbidities differed in overall survival (71.7 versus 90.2 months; P<0.001) and progression-free survival (21.0 versus 31.5 months; P<0.01). After adjustment for other prognostic factors and treatment, comorbidity maintained its independent prognostic value in a multivariate Cox regression analysis. Chronic lymphocytic leukemia was the major cause of death in patients with two or more comorbidities. Disease control in patients with two or more comorbidities was better with fludarabine plus cyclophosphamide than with fludarabine treatment, but not with fludarabine compared to chlorambucil treatment. These results give insight into interactions between comorbidity and therapy of chronic lymphocytic leukemia and suggest that durable control of the hematologic disease is most critical to improve overall outcome of patients with increased comorbidity. The registration numbers of the trials reported are NCT00276848 and NCT00262795.

Published
2014

48. Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Author

Modest, Dominik P., Stintzing, Sebastian, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kiani, Alexander, Vehling‐Kaiser, Ursula, Al‐Batran, Salah‐Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Scheithauer, Werner, Kirchner, Thomas, Jung, Andreas, Stauch, Martina, von Einem, Jobst Christian, Moehler, Markus, Held, Swantje, and Heinemann, Volker

Abstract

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to <20%), mPD (minor progression >0 to <20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8 (95% CI 11.1-14.5) months). Differences in PFS of first-line therapy were less pronounced. ETS subgroups defined in first-line therapy also correlated with efficacy of second-line therapy. Progression-free survival in second-line (PFS2nd) was 6.5 months (5.8-7.2) for ETS, and was 5.6 (95% CI 4.7-6.5) months for mETS, 4.9 (95% CI 3.7-6.1) months for mPD and 3.3 (95% CI 2.3-4.3) months for PD. PFS of first-line and PFS2nd showed a linear correlation (Bravais-Pearson coefficient: 0.16, p = 0.006). While ETS is associated with the most favorable outcome, non-ETS represents a heterogeneous subgroup with distinct characteristics of less favorable initial tumor response to treatment. This is the first analysis to demonstrate that early tumor response observed during first-line FOLFIRI-based therapy may also relate to efficacy of second-line treatment. Early response parameters may serve as stratification factors in trials recruiting pretreated patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

49. T-Rex study: Quality of life assessment using novel CTCAE-PRO and FKSI-19 in first-line treatment of metastatic renal cell carcinoma with tivozanib.

Author

Grünwald, Viktor, Lange, Carsten, Ziske, Carsten, Hegemann, Miriam, Seseke, Sandra, Fieseler, Claus, Standhaft, Diana, Janitzky, Andreas, Stauch, Martina, Marschner, Norbert, Distelrath, Andrea, Boegemann, Martin, Rau, Olrik, Baumann, Steffen, Hellmis, Eva, Dieckhoff, Jan, Brenneis, Horst, Rußwurm, Karen, Ivanyi, Philipp, and Doehn, Christian

Published
2023
Full Text
View/download PDF

50. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Author

Rummel, Mathias J., primary, Balser, Christina, additional, Kaiser, Ulrich, additional, Böck, Hans Peter, additional, Stauch, Martina Beate, additional, Heider, Andrea, additional, Welslau, Manfred, additional, Losem, Christoph, additional, Weidmann, Eckhart, additional, Blau, Wolfgang, additional, Burchardt, Alexander, additional, Barth, Jürgen, additional, Kauff, Frank, additional, Hinke, Axel, additional, and Brugger, Wolfram, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results